Table 2.
Demographics and clinical characteristics
| Remission at week 54 | Nonremission at week 54 | p value | |
|---|---|---|---|
| Baseline | |||
| Patients, n | 8 | 18 | |
| Male/female, n | 5/3 | 9/9 | 0.555 |
| Age, median (IQR), years | 48.5 (41.5–55.5) | 58 (33.3–64) | 0.505 |
| Weight, median (IQR), kg | 56.8 (52.5–58.5) | 62.2 (52.5–70) | 0.597 |
| Duration of disease, median (IQR), years | 6.7 (1.2–19.3) | 1.2 (0.8–7.3) | 0.211 |
| UC location, left side/extensive, n | 3/5 | 4/14 | 0.418 |
| Concomitant immunomodulator, n (%) | 4 (50) | 5 (27.8) | 0.272 |
| Partial Mayo score, median (IQR) | 6 (3–6.5) | 7 (5.3–8) | 0.128 |
| WBC, median (IQR), /µL | 8,135 (3,940–9,635) | 7,890 (5,312–10,445) | 0.803 |
| Hb, median (IQR), g/dL | 12.9 (11.9–14.8) | 12.4 (11.5–13.5) | 0.331 |
| Platelet, median (IQR), 104/µL | 31.6 (22.4–35.8) | 29.4 (25.3–36.5) | 0.978 |
| Albumin, median (IQR), g/dL | 4.0 (3.7–4.2) | 3.8 (3.4–4.2) | 0.486 |
| CRP, median (IQR), mg/L | 0.33 (0.05–1.47) | 0.18 (0.10–1.83) | 0.934 |
| Week 14 | |||
| Patients, n | 8 | 11 | |
| Male/female, n | 5/3 | 6/5 | 0.729 |
| Age, median (IQR), years | 48.7 (41.7–55.7) | 59.2 (33.7–67.7) | 0.508 |
| Duration of disease, median (IQR), years | 6.9 (1.4–19.5) | 2.1 (1.0–8.3) | 0.385 |
| UC location, left side/extensive, n | 3/5 | 1/10 | 0.134 |
| Concomitant immunomodulator, n (%) | 4 (50) | 2 (18.2) | 0.141 |
| Partial Mayo score, median (IQR) | 0 (0–1.3) | 4.5 (2.3–6) | 0.003 |
| WBC, median (IQR), /µL | 4,515 (4,273–5,508) | 5,390 (4,295–7,855) | 0.433 |
| Hb, median (IQR), g/dL | 13 (12.6–14.8) | 12.1 (10.7–13.3) | 0.342 |
| Platelet, median (IQR), 104/µL | 20.3 (18.0–27.1) | 30.2 (24.3–34.2) | 0.047 |
| Albumin, median (IQR), g/dL | 4.2 (4.0–4.5) | 3.6 (3.4–3.9) | 0.031 |
| CRP, median (IQR), mg/L | 0.03 (0.01–0.05) | 0.35 (0.18–0.85) | 0.098 |
UC, ulcerative colitis; WBC, white blood cell; CRP, C-reactive protein; IQR, interquartile range.